The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,257 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Old Dominion University (ODU) to advance the development of a microneedle patch technology for delivering a cocktail of broadly neutralizing antibodies (BnAbs) as a novel approach to preventing HIV-1 transmission in breastfeeding infants.
The project aims to rigorously design and fabricate the microneedle patch, conduct in vitro and ex vivo characterization of the formulated BnAbs, and evaluate the safety, pharmacokinetics, and efficacy of the platform in preclinical rabbit and nonhuman primate models. This innovative delivery system is intended to provide long-lasting protection against HIV-1 infection for this vulnerable pediatric population, overcoming the limitations of current antiretroviral therapy options. The project will run from August 2024 through June 2029.
Generated 4/1/25, 4:06 AM